

ORTHOLOGIC CORP  
Form 8-K  
September 30, 2004

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K  
CURRENT REPORT**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

---

Date of Report: September 29, 2004  
(Date of earliest event reported)  
**ORTHOLOGIC CORP.**

---

(Exact name of registrant as specified in its charter)

**Delaware**

**000-21214**

**86-0585310**

---

(State or other jurisdiction of  
incorporation)

---

(Commission File Number)

---

(I.R.S. Employer  
Identification No.)

---

**1275 West Washington Street, Tempe, Arizona**

---

**85281**

---

(Address of principal executive offices)

---

(Zip Code)

Registrant's telephone number, including area code:  
(602) 286-5520

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 7.01 Regulation FD Disclosure.

Item 9.01 Financial Statements and Exhibits.

**SIGNATURES**

Exhibit 99.1

Exhibit 99.2

---

**Table of Contents**

**Section 7 Regulation FD**

**Item 7.01 Regulation FD Disclosure.**

On September 29, 2004, Thomas R. Trotter, Chief Executive Officer of OrthoLogic Corp. (the Company), and James T. Ryaby, Ph. D, the Company's Senior Vice President of Research and Clinical Affairs and Chief Technology Officer, delivered a presentation at the UBS Global Life Sciences Conference in New York City, which was available to the public via a live webcast. The purpose of the presentation was to provide an update on the development of the Company's Chrysalin® product platform. The foregoing description is qualified by reference to the exhibits furnished with this Current Report on Form 8-K (this Report).

A full transcript of the presentation at the UBS Global Life Sciences Conference and copies of the slides used in such presentation will be available on the Company's website at [www.orthologic.com](http://www.orthologic.com). The full transcript of the presentation is furnished as Exhibit 99.1 to this Report and the copies of the slides used in such presentation are furnished as Exhibit 99.2 to this Report.

The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in the Company's expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based. Although the text included with this Report will be available on the Company's website, the Company expressly reserves the right to discontinue that availability at any time.

**Section 9 Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Transcript of the Company presentation at the UBS Global Life Sciences Conference on September 29, 2004
99.2	Slides used in the Company presentation at the UBS Global Life Sciences Conference on September 29, 2004

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 30, 2004

ORTHOLOGIC CORP.

/s/ Sherry A. Sturman  
Sherry A. Sturman  
Senior Vice President and  
Chief Financial Officer